AD-O53.2--a novel recombinant fusion protein combining the activities of TRAIL/Apo2L and Smac/Diablo, overcomes resistance of human cancer cells to TRAIL/Apo2L

MLA

Anna Pieczykolan, et al. “AD-O53.2--a Novel Recombinant Fusion Protein Combining the Activities of TRAIL/Apo2L and Smac/Diablo, Overcomes Resistance of Human Cancer Cells to TRAIL/Apo2L.” Investigational New Drugs, vol. 32, no. 6, June 2014. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....fb64508a340c32d5ed0dfcdadde6cd8e&authtype=sso&custid=ns315887.

APA

Anna Pieczykolan, Katarzyna Bukato, Sebastian Pawlak, Katarzyna Poleszak, Maciej Masłyk, Albert Jaworski, Konrad Kubiński, Marlena Gałązka, Jerzy Pieczykolan, Wojciech Strozek, Piotr Rózga, Rafal Zielinski, Malgorzata Teska-Kaminska, Michal Szymanik, Bartłomiej Żerek, & Robert Świder. (2014). AD-O53.2--a novel recombinant fusion protein combining the activities of TRAIL/Apo2L and Smac/Diablo, overcomes resistance of human cancer cells to TRAIL/Apo2L. Investigational New Drugs, 32(6).

Chicago

Anna Pieczykolan, Katarzyna Bukato, Sebastian Pawlak, Katarzyna Poleszak, Maciej Masłyk, Albert Jaworski, Konrad Kubiński, et al. 2014. “AD-O53.2--a Novel Recombinant Fusion Protein Combining the Activities of TRAIL/Apo2L and Smac/Diablo, Overcomes Resistance of Human Cancer Cells to TRAIL/Apo2L.” Investigational New Drugs 32 (6). http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....fb64508a340c32d5ed0dfcdadde6cd8e&authtype=sso&custid=ns315887.